Position in NTRA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$105,594,050
+$31,277,167 QoQ
Shares Held
389,000
+4.7% QoQ
Ownership
0.270%
of shares outstanding
% of Portfolio
2.74%
of 13F equity value
Holder Rank
#60
of 844 holders
Holding Since
Sep 2021
11 quarters on record
Voting authority
Sole 72%
Shared 0%
None 28%
Common Shares in NTRA Over Time
Shares Held
Position Value (USD)
Derivatives in NTRA
reported options exposure · as of Mar 31, 2025CallValue
$0
CallShares
0
PutValue
$74,890,736
PutShares
529,600
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $270,450,827 across 3 Diagnostics & Research names. NTRA ranks #2 (39.0% of the industry book) .
All Filings in NTRA
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $105,594,050 | 389,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $74,316,883 | 371,603 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $93,389,225 | 407,653 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $19,893,799 | 123,587 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $15,429,290 | 91,330 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $80,427,785 | 568,756 | Shares | Sole | 2025-05-15 | |
| 2025-03-31 | $74,890,736 | 529,600 | Put | Sole | 2025-05-15 | |
| 2024-12-31 | $116,112,733 | 733,498 | Shares | Sole | 2025-02-14 | |
| 2024-12-31 | $90,231,000 | 570,000 | Put | Sole | 2025-02-14 | |
| 2024-09-30 | $74,230,965 | 584,726 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $61,097,759 | 564,205 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $56,933,667 | 622,498 | Shares | Sole | 2024-05-15 | |
| 2021-09-30 | $382,127 | 3,429 | Shares | Sole | 2021-11-15 | |
| No filing history on record for this holder in this stock. | ||||||